Abstract
Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide. Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and treat disease, has been shown to be a promising approach for combating PCa. In PCa patients, bone is one of the most common sites of metastases, and about 90% of patients develop bone metastases. This review focuses on (i) clinically translated theragnostic radionuclide pairs for the management of PCa, (ii) radionuclide therapy of bone metastases in PCa, and (iii) a special emphasis on emerging theragnostic radionuclide pair, Copper-64/Copper-67 (64Cu/67Cu) for managing the disease.
Funder
NIH
Philadelphia prostate cancer Biome project
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference78 articles.
1. Leslie, S.W., Soon-Sutton, T.L., Sajjad, H., and Siref, L.E. Prostate cancer. StatPearls, 2022.
2. Global trends and prostate cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location;Taitt;Am. J. Mens Health,2018
3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
4. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations—Total U.S. (1969–2020). 2022.
5. Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis;He;Medicine,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献